Skip to main content
All lobbying filings

AMGEN, INC.

Lobbying for AMGEN INC

 Filing 1st Quarter - Report
1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · House · Senate · $2,580,000.00 expenses · posted Apr 20, 2026

Official filing document

 Bills named in this filing 26
  • HR 1492
    To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
  • HR 1672
    Maintaining Investments in New Innovation Act
  • HR 1
    An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
  • HCONRES 14
    Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appro…
  • S 3345
    PBM Price Transparency and Accountability Act
  • HR 6166
    Lowering Drug Costs for American Families Act
  • S 3019
    No Big Blockbuster Bailouts Act
  • HR 4317
    PBM Reform Act of 2025
  • HR 4299
    Protecting Patient Access to Cancer and Complex Therapies Act
  • HR 7837
    Most Favored Patient Act of 2026
  • HR 5256
    340B ACCESS Act
  • HR 5526
    Biosimilar Red Tape Elimination Act
  • HR 7391
    Community Health Center Drug Pricing Protection Act
  • S 1041
    Affordable Prescriptions for Patients Act
  • S 1040
    Drug Competition Enhancement Act
  • HR 1574
    RESTORE Patent Rights Act of 2025
  • S 1553
    PREVAIL Act
  • HR 3160
    PREVAIL Act
  • S 1546
    Patent Eligibility Restoration Act of 2025
  • HR 3152
    Patent Eligibility Restoration Act of 2025
  • HR 3269
    ETHIC Act
  • S 43
    Skinny Labels, Big Savings Act
  • HR 6485
    Skinny Labels, Big Savings Act
  • S 2658
    Medication Affordability and Patent Integrity Act
  • S 3452
    Biological Intellectual Property Protection Act of 2025
  • HR 6624
    Biological Intellectual Property Protection Act of 2025
 Lobbying activity 5
Health Issues

Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act H.R.5526 Biosimilar Red Tape Elimination Act HR 7391 Community Health Center Drug Pricing Protection Act

Medicare/Medicaid

Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S.3345, PBM Price Transparency and Accountability Act HR 6166, Lowering Drug Costs for American Families Act S 3019 - No Big Blockbuster Bailouts Act S 3349 PBM Disclosure Act HR 4317 PBM Reform Act Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act (EPIC) HR 1672 Maintaining Investments in New Innovation Act (MINI) HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 PL 119-75 Consolidated Appropriations Act of 2026

Taxation/Internal Revenue Code

Issues related to corporate and international tax Public Law 115-97, Tax Cuts and Jobs Act Public Law 119-21, One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) Issues related to Puerto Rico Issues related to OECD negotiations on the taxation of global income

Copyright/Patent/Trademark

Federal Trade Commission related issues Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS Issues related to patent thickets Issues related to obviousness/ double patenting Issues related to FDA/PTO coordination Issues related to skinny labeling S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S 708/ HR 1574 -- Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE) S.1553/HR3160-- Promoting and Respecting Economically Viable American Innovation Act (PREVAIL) S. 1546/ HR 3152-- Patent Eligibility Restoration Act of 2025 (PERA) S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 43/HR 6485 Skinny Labels Big Savings Act S.2658 Medication Affordability and Patent Integrity Act S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025

Tariff (miscellaneous tariff bills)

Issues related to tariffs Issues related to trade agreements S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem